Drugs and FDA

Hims & Hers launches five compounded peptide and longevity treatments

Hims & Hers is offering five compounded treatments that are not approved by the FDA.

Reported by 3 outlets Wednesday, November 18, 2026

Capsules scattered on a wooden table
Photo: CC0

Hims & Hers said Wednesday it is offering five U.S.-compounded formulations through its Peptides+ platform: sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine. The company said none of these specific compounded products is approved by the FDA.

Members will first have an assessment of their health history and goals with a licensed provider trained in peptide therapies. Hims said it plans to add more treatments over time, including BPC-157 and TB-500. The company acknowledged there is more to learn about how to use the treatments and how effective they are. CNBC reported that health experts raised concerns about limited human evidence and unknown dosing. The launch follows an HHS policy that CNBC said means the FDA will not take enforcement action against certain pharmacies and others compounding six unapproved peptides while formal rules are reviewed.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.